Skip to main content

Where the bodies lie – Bioentrepreneur

By August 12, 2016News
body-parts-veins-organs-pixa

body-parts-veins-organs-pixa

As members of a life sciences advisory and investment banking group, my partners and I have often noted that life sciences companies fall victim to the same mistakes and misconceptions, repeated again and again. These failures mostly hinge upon company management misunderstanding the fundamentals of market dynamics and failing to appreciate the importance of the exit—the sole event where company investors receive a return on their investment, either through an initial public offering (IPO) or a company sale. Unfortunately, the biotech industry’s track record on exits is disappointing. According to the National Venture Capital Association (Washington, DC), between 2005 and 2014, only one in five US biotech and medical device companies achieved liquidity after six years. And from my perspective over the past 20 years, that low success rate does not appear to be improving.

{iframe}http://www.nature.com/bioent/2016/160801/full/bioe.2016.8.html?spMailingID=52042241&spUserID=MTc1OTY1MzY5MTkzS0&spJobID=981976813&spReportId=OTgxOTc2ODEzS0{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.